Astellas Pharma Inc. is a prominent Japanese multinational pharmaceutical company, operating within the global Healthcare sector. As a key player in the Drug Manufacturers industry, the company holds a substantial market capitalization of 4.02 Trillion JPY, reflecting its significant presence in the research, development, and marketing of pharmaceutical products worldwide.

Based on our technical scoring system, Astellas Pharma Inc. currently receives a "Strong Sell" rating with a total score of -4. The primary driver for this bearish outlook is the long-term trend, as the current price is trading below its 200-day simple moving average, contributing -2 points. Further negative pressure is indicated by the MACD histogram, which is below zero, signaling ongoing bearish momentum (-1 point). Additionally, the On-Balance Volume (OBV) is below its moving average, suggesting that selling pressure is currently outpacing buying interest, a sign of distribution (-1 point). Indicators for trend strength (ADX) and momentum (RSI) are currently in neutral territory, not adding to the score but failing to provide any bullish counter-signals.

The technical "Strong Sell" rating finds significant support in the company's recent fundamental performance. The latest earnings report revealed a staggering negative surprise of -5573.0% on its reported EPS of 12.07, a major red flag for investors. While the P/E ratio of 13.83 might seem attractive on the surface, this massive earnings miss overshadows its valuation. The company's dividend yield is also notably high, which may warrant further investigation. With the next earnings report not scheduled until on 29/10/2026, the market has a long period to factor in this poor performance, reinforcing the bearish technical signals and suggesting caution is warranted for the foreseeable future.